Cedric K. Olivera

Cedric K. Olivera

Auto-generated profile, based on publicly available information

Cedric K. Olivera

Mount Sinai School of Medicine

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
DRDavid D. Rahn
David D. Rahn
CCCassandra Carberry
Cassandra Carberry
TSTatiana V. Sanses
Tatiana V. Sanses
MMMamta M. Mamik
Mamta M. Mamik
RWRenée M. Ward
Renée M. Ward
MMMiles Murphy
Miles Murphy
OBJECTIVE: To comprehensively review and critically assess the literature on vaginal estrogen and its alternatives for women with genitourinary syndrome of menopause and to provide clinical practice guidelines. DATA SOURCES: MEDLINE and Cochrane databases were searched from inception to April 2013. We included randomized controlled trials and prospective comparative studies. Interventions and comparators included all commercially available vaginal estrogen products. Placebo, no treatment, systemic estrogen (all routes), and nonhormonal moisturizers and lubricants were included as comparators. METHODS OF STUDY SELECTION: We double-screened 1,805 abstracts, identifying 44 eligible studies. Discrepancies were adjudicated by a third reviewer. Studies were individually and collectively assessed for methodologic quality and strength of evidence. TABULATION, INTEGRATION, AND RESULTS: Studies were extracted for participant, intervention, comparator, and outcomes data, including patient-reported atrophy symptoms (eg, vaginal dryness, dyspareunia, dysuria, urgency, frequency, recurrent urinary tract infection (UTI), and urinary incontinence), objective signs of atrophy, urodynamic measures, endometrial effects, serum estradiol changes, and adverse events. Compared with placebo, vaginal estrogens improved dryness, dyspareunia, urinary urgency, frequency, and stress urinary incontinence (SUI) and urgency urinary incontinence (UUI). Urinary tract infection rates decreased. The various estrogen preparations had similar efficacy and safety; serum estradiol levels remained within postmenopausal norms for all except high-dose conjugated equine estrogen cream. Endometrial hyperplasia and adenocarcinoma were extremely rare among those receiving vaginal estrogen. Comparing vaginal estrogen with nonhormonal moisturizers, patients with two or more symptoms of vulvovaginal atrophy were substantially more improved using vaginal estrogens, but those with one or minor complaints had similar symptom resolution with either estrogen or nonhormonal moisturizer. CONCLUSION: All commercially available vaginal estrogens effectively relieve common vulvovaginal atrophy-related complaints and have additional utility in patients with urinary urgency, frequency or nocturia, SUI and UUI, and recurrent UTIs. Nonhormonal moisturizers are a beneficial alternative for those with few or minor atrophy-related symptoms and in patients at risk for estrogen-related neoplasia. CLINICAL TRIAL REGISTRATION: PROSPERO International prospective register of systematic reviews, http://www.crd.york.ac.uk/PROSPERO/ , CRD42013006656.

1 August 2018 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
KMKate V. Meriwether
Kate V. Meriwether
DADanielle D. Antosh
Danielle D. Antosh
COCedric K. Olivera
Cedric K. Olivera
SKShunaha Kim-Fine
Shunaha Kim-Fine
EBEthan Balk
Ethan Balk
DRDavid D. Rahn
David D. Rahn

1 January 2015 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
NSNazema Y. Md Siddiqui
Nazema Y. Md Siddiqui
CGCara L. Grimes
Cara L. Grimes
ECElizabeth R. Casiano
Elizabeth R. Casiano
HAHusam T. Abed
Husam T. Abed
PJPeter C. Jeppson
Peter C. Jeppson
VSVivian W. Sung
Vivian W. Sung
OBJECTIVE: To systematically review outcomes after mesh sacrocolpopexy compared with native tissue vaginal repairs in women with apical prolapse. DATA SOURCES: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov through June 4, 2012. METHODS OF STUDY SELECTION: For anatomic and functional analyses, we included studies comparing mesh sacrocolpopexy to native tissue vaginal repairs with at least 6 months follow-up. The primary outcome was anatomic “success” after surgery. Secondary outcomes were reoperation and symptom outcomes. We included large case series and comparative studies with shorter follow-up to increase power for adverse event analyses. TABULATION, INTEGRATION, AND RESULTS: Evidence quality was assessed with the Grades for Recommendation, Assessment, Development and Evaluation system. Meta-analyses were performed when at least three studies reported the same outcome. We included 13 comparative studies for anatomic success, reoperation, and symptom outcomes. Moderate-quality evidence supports improved anatomic outcomes after mesh sacrocolpopexy; very low-quality evidence shows no differences in reoperation between sacrocolpopexy and native tissue vaginal repairs. Evidence was insufficient regarding which procedures result in improved bladder or bowel symptoms. Low-quality evidence showed no differences in postoperative sexual function. Adverse event data were compiled and meta-analyzed from 79 studies. When including larger noncomparative studies, ileus or small bowel obstruction (2.7% compared with 0.2%, P<.01), mesh or suture complications (4.2% compared with 0.4%, P<.01), and thromboembolic phenomena (0.6% compared with 0.1%, P=.03) were more common after mesh sacrocolpopexy compared with native tissue vaginal repairs. CONCLUSION: When anatomic durability is a priority, we suggest that mesh sacrocolpopexy may be the preferred surgical option. When minimizing adverse events or reoperation is the priority, there is no strong evidence supporting one approach over the other.

1 May 2014 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
RGRajiv B. Gala
Rajiv B. Gala
RMRebecca Margulies
Rebecca Margulies
ASAdam Steinberg
Adam Steinberg
MMMiles Murphy
Miles Murphy
JLJames Lukban
James Lukban
VSVivian Sung
Vivian Sung

13 November 2014 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
FGfor the Society of Gynecologic Surgeons Systematic Review Group
for the Society of Gynecologic Surgeons Systematic Review Group
DRDavid D. Rahn
David D. Rahn
RWRenée M. Ward
Renée M. Ward
TSTatiana V. Sanses
Tatiana V. Sanses
CCCassandra Carberry
Cassandra Carberry
MMMiles Murphy
Miles Murphy

29 June 2012 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
TFTola B. Omotosho Fashokun
Tola B. Omotosho Fashokun
FNfor the Society of Gynecologic Surgeons’ Fellows’ Pelvic Research Network
for the Society of Gynecologic Surgeons’ Fellows’ Pelvic Research Network
HHHeidi S. Harvie
Heidi S. Harvie
MSMegan O. Schimpf
Megan O. Schimpf
COCedric K. Olivera
Cedric K. Olivera
RRRebecca G. Rogers
Rebecca G. Rogers